{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:53:37Z","timestamp":1789750417869,"version":"4.0.1"},"reference-count":15,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Respiratory J"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Tobramycin inhalation solution (TIS) is a treatment option for patients with frequent exacerbations of bronchiectasis. A possible side effect of TIS is the development of chronic cough and bronchospasm, whereby the guidelines suggest a (in hospital) tolerance test with the first dose of TIS. However, data on respiratory adverse events are not consistent. In the present analysis from the BATTLE study (NCT02657473), we evaluated the added value of the tolerance test and aimed to observe the development of inhaled treatment related bronchial hyperreactivity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Fifty\u2010seven patients from the BATTLE study were analyzed. Patients were randomized to receive TIS or placebo OD for 1\u00a0year. A tolerance test was performed with spirometry measurements before and after the first dose and with a bronchodilator in advance. Adverse events were strictly monitored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifty\u2010seven patients (100%) passed the tolerance test with no decrease in spirometry measurements or development of local intolerability. During the study treatment, a total of five TIS\u2010treated patients (17.8%) withdrew due to airway hyperresponsiveness after a mean of 9.2 (SD13.9) weeks and one placebo\u2010treated patient (3.5%) after 2\u00a0weeks (TIS vs. placebo;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.66). The other TIS\u2010related adverse events were not clinically significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The use of inhaled medication is well tolerated in the heterogenous bronchiectasis population, without signs of airway hyperresponsiveness after the first dose of inhaled medication. From this observation, it can be concluded that there is no additional value for this advised tolerance test. However, closely monitoring on adverse effects during the first weeks after starting TIS is recommended.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/crj.13663","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T22:30:31Z","timestamp":1689633031000},"page":"748-753","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Treatment with inhaled antibiotics in bronchiectasis, side effects, and evaluation of the tolerance test; analysis from the BATTLE randomized controlled trial"],"prefix":"10.1111","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7010-7071","authenticated-orcid":false,"given":"Lotte C.","family":"Terpstra","sequence":"first","affiliation":[{"name":"Department of pulmonary medicine Northwest Clinics Alkmaar  Alkmaar The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"van der Geest","sequence":"additional","affiliation":[{"name":"Department of pulmonary medicine Northwest Clinics Alkmaar  Alkmaar The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inez","family":"Bronsveld","sequence":"additional","affiliation":[{"name":"Department of pulmonary medicine University Medical Centre Utrecht  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Heijerman","sequence":"additional","affiliation":[{"name":"Department of pulmonary medicine University Medical Centre Utrecht  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim G.","family":"Boersma","sequence":"additional","affiliation":[{"name":"Department of pulmonary medicine Northwest Clinics Alkmaar  Alkmaar The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00629\u20102017"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20102600(19)30185\u20107"},{"key":"e_1_2_10_4_1","unstructured":"TerpstraLC BoersmaWG.Effects of long\u2010term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non\u2010cystic fibrosis bronchiectasis the BATTLE randomized controlled trial."},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00018414"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.162.2.9910086"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E099"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.127.4.1420"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01451\u20102020"},{"key":"e_1_2_10_10_1","unstructured":"NVALT.Richtlijn Diagnostiek en behandeling van pati\u00ebnten met bronchi\u00ebctasie\u00ebn.2017. Retrieved May 18 2018 fromhttps:\/\/www.nvalt.nl\/kwaliteit\/richtlijnen\/infectieziekten"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12931\u2010022\u201002243\u2010y"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2022.101045"},{"key":"e_1_2_10_13_1","unstructured":"Manual I deluxe.http:\/\/incenter.medical.philips.com\/doclib\/enc\/10252061\/InnoSpireDeluxe_SalesAid.pdf%3ffunc%3ddoc.Fetch%26nodeid%3d10252061"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl\u20102014\u2010205587"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201312\u20102208OC"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901073400104"}],"container-title":["The Clinical Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/crj.13663","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T04:57:15Z","timestamp":1692680235000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/crj.13663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,17]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1111\/crj.13663"],"URL":"https:\/\/doi.org\/10.1111\/crj.13663","archive":["Portico"],"relation":{},"ISSN":["1752-6981","1752-699X"],"issn-type":[{"value":"1752-6981","type":"print"},{"value":"1752-699X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,17]]},"assertion":[{"value":"2022-06-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}